Salivary Extracellular MicroRNAs for Early Detection and Prognostication of Esophageal Cancer: A Clinical Study

Lin, Yusheng; Zhou, Yujie; Xiong, Xi; Wang, Lu; Li, Junkuo; Zhou, Fuyou; Guo, Ye; Chen, Shaobin; Chen, Yuping; Tang, Hui; Qiu, Xiaoyu; Cai, Song-Wang; Zhang, Dianzheng; Bremer, Edwin; Yeung, Sai‐Ching Jim; Zhang, Hao

doi:10.1053/j.gastro.2023.06.021

Cited by 20 publications

(3 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We then aimed to validate the previous findings by recruiting another PwP cohort, which was used as the validation cohort. In our literature review, we found that miR-4274 has been reported in diseases associated with esophageal squamous cell carcinoma [ 24 ] and normal-pressure hydrocephalus [ 25 ], but not neurodegeneration. We therefore did not rank this microRNA as a high priority in the validation phase.…”

Section: Resultsmentioning

confidence: 99%

Plasma miR-203a-3p as a Novel Predictor of Dementia in Patients with Parkinson’s Disease

Hsu,

Lin,

Chu

et al. 2024

IJMS

View full text Add to dashboard Cite

The early detection of cognitive decline in Parkinson’s disease is important for providing drug therapy and non-pharmacological management. The circulating microRNAs present in plasma are promising biomarkers of PD with dementia (PDD) due to their critical roles in synaptic plasticity and the regulation of neurodegeneration-associated proteins. In this study, we aimed to identify plasma microRNAs that may differentiate PD with or without cognitive impairment. Global microRNA expression was obtained from a discovery set of 123 participants who were divided into four groups, namely normal controls (HC), PD with no dementia (PDND), PD with mild cognitive impairment (PD-MCI), and PDD, using next-generation sequencing. The BOLD selector was used for microRNA candidate selection. Six miRNAs, namely miR-203a-3p, miR-626, miR-662, miR-3182, miR-4274, and miR-4295, were clustered as potential candidates for use in identifying PDND from PD-MCI. Another independent cohort of 120 participants was further recruited in a validation step in order to detect candidate microRNAs via droplet digital PCR (ddPCR), which was used for its high sensitivity in detecting low miRNA concentrations. Our results show that the ratio of miR-203a-3p/miR-16-5p, in which miR-16-5p was used as a reference control miRNA, was significantly increased in PDD compared to that seen in PD-MCI and PDND individually, and was negatively correlated with the MoCA scores (r = −0.237, p = 0.024) in patients with PD. However, there was no significant difference in the ratio of miR-203a-3p/miR-16-5p between HC and PDND, PD-MCI, or PDD individually. The ROC curve of the logistic regression model, factoring in the variables of age, the ratio of miR-203a-3p/miR-16-5p, and the UPDRS III score, demonstrated an AUC of 0.883. Our findings suggest that the ratio of miR-203a-3p/miR-16-5p, used with age and motor score, could be a predictor of dementia among PD patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Plasma miR-203a-3p as a Novel Predictor of Dementia in Patients with Parkinson’s Disease

Hsu,

Lin,

Chu

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…Our previous findings revealed that miR-503 from pancreatic islet β-cells reaches the liver and adipose tissue in the form of exosomes, which are known to transport biologically active proteins and miRNAs in their active forms to neighboring cells or distant organs. [38][39][40] Thus, the involvement of exosomes in inter-organ and intra-organ crosstalk has been increasingly studied. 41,42 Exosomes derived from mesenchymal stem cells have been reported as a new treatment for AP by delivering mitochondria and anti-inflammatory factors.…”

Section: Discussionmentioning

confidence: 99%

Endocrine-exocrine miR-503-322 drives aging-associated pancreatitis via targeting MKNK1 in acinar cells

Zhu,

Liu,

et al. 2024

Preprint

View full text Add to dashboard Cite

Aging is the major risk factor for chronic pancreatitis and severity determinant for its acute attack, yet the underlying cause is unclear. Here, we demonstrate that senescent β-cells of endocrine pancreas decide the onset and severity of chronic and acute pancreatitis. During physiological aging, senescent β-cells increase the expression of miR-503-322 which is secreted as nano-vesicles to enter exocrine acinar cells, driving a causal and reversible role on aging-associated pancreatitis. Mechanistically, miR-503-322 represses MKNK1 to inhibit acinar-cell secretion and proliferation, thereby causing autodigestion and repairing damage of exocrine pancreas. In the elderly population, serum miR-503 concentration is negatively correlated with amylase, prone to chronic pancreatitis due to increased miR-503 and decreased MKNK1 in the elderly pancreas. Our findings highlight the miR-503-322–MKNK1 axis mediating the endocrine-exocrine regulatory pathway specifically in aged mice and humans. Modulating this axis may provide potential preventive and therapeutic strategies for aging-associated pancreatitis.

show abstract

“…Despite exceeding advancements in the diagnostic modalities and treatment strategies available for ESCC, effectively managing this condition remains a formidable challenge due to the absence of specific early-stage symptoms, the substantial potential for metastasis and recurrence, and resistance to traditional therapeutic approaches. The likelihood of patients with advanced-stage ESCC surviving is merely 10%-20% over a span of 5 years[ 4 ]. The timely identification and diagnosis of ESCC are of paramount importance for increasing the likelihood of eligibility for curative surgical resection[ 5 ].…”

Section: Introductionmentioning

confidence: 99%

Novel milestones for early esophageal carcinoma: From bench to bed

Qi,

Huang,

Jin

2024

World J Gastrointest Oncol

View full text Add to dashboard Cite

Esophageal cancer (EC) is the seventh most common cancer worldwide, and esophageal squamous cell carcinoma (ESCC) accounts for the majority of cases of EC. To effectively diagnose and treat ESCC and improve patient prognosis, timely diagnosis in the initial phase of the illness is necessary. This article offers a detailed summary of the latest advancements and emerging technologies in the timely identification of ECs. Molecular biology and epigenetics approaches involve the use of molecular mechanisms combined with fluorescence quantitative polymerase chain reaction (qPCR), high-throughput sequencing technology (next-generation sequencing), and digital PCR technology to study endogenous or exogenous biomolecular changes in the human body and provide a decision-making basis for the diagnosis, treatment, and prognosis of diseases. The investigation of the microbiome is a swiftly progressing area in human cancer research, and microorganisms with complex functions are potential components of the tumor microenvironment. The intratumoral microbiota was also found to be connected to tumor progression. The application of endoscopy as a crucial technique for the early identification of ESCC has been essential, and with ongoing advancements in technology, endoscopy has continuously improved. With the advancement of artificial intelligence (AI) technology, the utilization of AI in the detection of gastrointestinal tumors has become increasingly prevalent. The implementation of AI can effectively resolve the discrepancies among observers, improve the detection rate, assist in predicting the depth of invasion and differentiation status, guide the pericancerous margins, and aid in a more accurate diagnosis of ESCC.

show abstract

Salivary Extracellular MicroRNAs for Early Detection and Prognostication of Esophageal Cancer: A Clinical Study

Cited by 20 publications

References 62 publications

Plasma miR-203a-3p as a Novel Predictor of Dementia in Patients with Parkinson’s Disease

Plasma miR-203a-3p as a Novel Predictor of Dementia in Patients with Parkinson’s Disease

Endocrine-exocrine miR-503-322 drives aging-associated pancreatitis via targeting MKNK1 in acinar cells

Novel milestones for early esophageal carcinoma: From bench to bed

Contact Info

Product

Resources

About